AAX Biotech AB
PrivateLast Round
VC Round
Feb 19, 2026
Momentum
Top 50%
of companies Caplight tracks
Company Overview
AAX Biotech AB is a biotechnology company that develops proprietary antibody engineering technologies, including Seqitope and Opti-mAb, to improve the performance and developability of next-generation antibody therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AAX Biotech AB Comparables
Compare AAX Biotech AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ProteoGenix | 76% | |
| AvantGen, Inc. | 76% | |
| Adimab | 72% |
AAX Biotech AB Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Feb 19, 2026 | ||||
| VC Round | Oct 2, 2024 |
Key People
Founding team and executive leadership
AAX Biotech AB Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Trio Impact Invest | VC Round |
| Phase2Phase Biopharma | VC Round |
| Life Science Invest | VC Round |
| Northislet AB | VC Round |
| Karolinska Institutet Holding | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 19, 2026
$555K round led by Trio Impact Invest
- Aug 22, 2025
Grew 43% QoQ from 7 to 10 employees.
Recent news
Latest coverage and updates
- recognized_asSep 10, 2026
AAX Biotech AB recognized as best Innovation Poster at Innovation Poster Exhibition.
- partners_withAug 31, 2026
AAX Biotech AB partnered with Daiichi Sankyo Europe GmbH on Aug 31st '26.
- attends_eventAug 19, 2026
AAX Biotech AB attends event Nordic Life Science Days 2026.
AAX Biotech AB Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about AAX Biotech AB's valuation, stock price, and market status.
Is AAX Biotech AB a public or private company?
AAX Biotech AB is a private company.
What is the current stock price of AAX Biotech AB?
AAX Biotech AB is a private company with no public stock price. No recent secondary market data is available.
How much is AAX Biotech AB worth (valuation)?
Valuation information for AAX Biotech AB is not publicly available.
Can I buy AAX Biotech AB stock?
AAX Biotech AB shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was AAX Biotech AB's last funding round?
AAX Biotech AB's most recent funding round was VC Round on February 19, 2026.
Who are the main investors in AAX Biotech AB?
Key investors in AAX Biotech AB include Trio Impact Invest.
Will AAX Biotech AB IPO soon?
No public IPO plans have been announced for AAX Biotech AB.
How can I track AAX Biotech AB secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AAX Biotech AB's secondary market activity and sign up for updates.